Abstract
In this meta-analysis, the investigators reviewed the use of antipsychotics for treating behavioral and psychological symptoms in dementia (BPSD) and the potential side effect of decline in cognitive function from ten randomized placebo-controlled trials (RCTs).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wolf A, Leucht S, Pajonk FG. Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 2017;267(3):187–98.
Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS, CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844–54.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kim, S., Holsinger, T. (2022). Do Antipsychotics Lead to Cognitive Impairment in Dementia? A Meta-analysis of Randomized Placebo-Controlled Trials. In: Tampi, R.R., Tampi, D.J., Young, J.J., Balasubramaniam, M., Joshi, P. (eds) Essential Reviews in Geriatric Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-030-94960-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-94960-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-94959-4
Online ISBN: 978-3-030-94960-0
eBook Packages: MedicineMedicine (R0)